# US 10,500,258 B2 · DNA vaccines and methods for the prevention of transplantation rejection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,258 B2
- Document ID: US10500258B2
- Status: Granted
- Kind: B2
- Application number: 15/172,937
- Filed: 2016-06-03
- Published: 2017-02-02
- Granted: 2019-12-10
- Earliest claimed: 2005-05-11
- Assignees: Loma Linda University
- Applicants: Loma Linda University
- Inventors: Fengchun Li; Alan P. Escher
- Web page: https://patentgrep.com/patent/US10500258B2

## CPC

- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/577: {tolerising response}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for preventing, delaying the onset of, or treating rejection of an allograft using a DNA vaccine, where the vaccine can comprise a polynucleotide encoding a pro-apoptotic protein, like BAX and/or a polynucleotide encoding an autoantigen or donor antigen, like secreted glutamic acid decarboxylase 55. Administering one of the DNA vaccines to a transplant recipient, as described herein, can induce a donor specific tolerogenic response.

## Claims

### Claim 1

A method for inducing a tolerogenic response, comprising intradermally administering to a graft or transplant recipient an effective amount of a DNA vaccine composition, thereby inducing a tolerogenic response to prevent or minimize (i) late-onset chronic graft or transplant rejection, and/or (ii) transplant induced autoimmunity,
wherein the DNA vaccine composition comprises (a) a first plasmid comprising a polynucleotide encoding a pro-apoptotic protein operably linked to a promoter that controls the expression of the polynucleotide encoding the pro-apoptotic protein, wherein the encoded pro-apoptotic protein is selected from the group consisting of BAX (SEQ ID NO.:2), Death Receptor 3 (DR3), Death Receptor 4 (DR4), Death Receptor 5 (DR5), and a FAS receptor; and (b) a second plasmid comprising a polynucleotide encoding an autoantigen or a donor antigen operably linked to a promoter that controls the expression of the polynucleotide encoding the autoantigen or donor antigen, and comprising a plurality of CpG motifs, wherein at least some of the plurality of CpG motifs are methylated and resistant to digestion by restriction endonuclease HpaII.

### Claim 2 (depends on 1)

The method of claim 1, wherein the graft or transplant comprise tissues or organs selected from the group consisting of skin grafts, islet cell transplants, and partial or whole organ transplants.

### Claim 3 (depends on 2)

The method of claim 2, wherein the partial or whole organ transplants are selected from the group consisting of hearts, lungs, kidneys and livers.

### Claim 4 (depends on 1)

The method of claim 1, wherein the first and/or second plasmid is methylated with an SssI DNA methyltransferase.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first plasmid and second plasmid contain the same promoter.

### Claim 6 (depends on 1)

The method of claim 1, wherein the DNA vaccine comprises the first plasmid and the second plasmid in a ratio of between 1/10 to 10/1.

### Claim 7 (depends on 1)

The method of claim 1, wherein the autoantigen or donor antigen is selected from the group consisting of carbonic anhydrase II, collagen, CYP2D6 (cytochrome P450, family 2, subfamily Device 400, polypeptide 6), glutamic acid decarboxylase, secreted glutamic acid decarboxylase 55 (SEQ ID NO:1), insulin, myelin basic protein and SOX-10 (SRY-box containing gene 10).

### Claim 8 (depends on 1)

The method of claim 1, wherein the DNA vaccine prevents or minimizes late-onset chronic allograft or allogeneic transplant rejection.

### Claim 9 (depends on 1)

The method of claim 1, wherein the DNA vaccine is administered in a plurality of doses.

### Claim 10 (depends on 1)

The method of claim 1, wherein the DNA vaccine is administered weekly between two times and 100 times.

### Claim 11 (depends on 1)

The method of claim 1, wherein the DNA vaccine is administered proximal to the graft or transplant site.

### Claim 12 (depends on 1)

The method of claim 1, further comprising administering an immunosuppressant agent before, on the day of, and/or after engraftment or transplantation.

### Claim 13 (depends on 12)

The method of claim 12, wherein the immunosuppressant agent is administered simultaneously, separately or sequentially with the DNA vaccine.

### Claim 14 (depends on 12)

The method of claim 12, wherein the immunosuppressant agent is selected from the group consisting of corticosteroids, glucocorticoids, cyclophosphamide, 6-mercaptopurine, azathioprine, methotrexate cyclosporine, mycophenolate mofetil, mycophenolic acid, tacrolimus, sirolimus, everolimus, mizoribine, leflunomide, deoxyspergualin, brequinar, azodicarbonamide, vitamin D analogs, antilymphocyte globulin, antithymocyte globulin, anti-CD3 monoclonal antibodies, anti-interleukin-2 receptor (anti-CD25) antibodies, anti-CD52 antibodies, anti-CD20 antibodies, anti-tumor necrosis factor reagents and LFA-1 inhibitors.

### Claim 15 (depends on 12)

The method of claim 12, comprising administering a single dose of anti-lymphocyte globulin, at a dose ranging from about 1.6 mg/20 g of body weight, on the day of engraftment or transplantation.

### Claim 16 (depends on 12)

The method of claim 12, comprising administering rapamycin at a dose ranging from 0.05 mg/day to 15 mg/day.